Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells

C. H. Jin, K. Kusuhara, Y. Yonemitsu, A. Nomura, S. Okano, H. Takeshita, M. Hasegawa, K. Sueishi, T. Hara

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Hematopoietic stem cells (HSCs) are a promising target for gene therapy, however, the low efficiencies of gene transfer using currently available vectors face practical limitations. We have recently developed a novel and efficient gene transfer agent, namely recombinant Sendai virus (SeV), and we have here characterized SeV-mediated gene transfer to human cord blood (CB) HSCs and primitive progenitor cells (PPC) using the jelly fish green fluorescent protein (GFP) gene. Even at a relatively low titer (10 multiplicity of infections), SeV achieved highly efficient GFP expression in CB CD34+ cells (85.5 ± 5.8%), as well as more immature CB progenitor cells, CD34+AC133+ (88.2 ± 3.7%) and CD34+CD38- (84.6 ± 5.7%) cells, without cytokines prestimulation, that was a clear contrast to the features of gene transfer using retroviruses. SeV-mediated gene transfer was not seriously affected by the cell cycle status. In vitro cell differentiation studies revealed that gene transfer occurred in progenitor cells of all lineages (GM-CFU, 73.0 ± 11.1%; BFU-E, 24.7 ± 4.0%; Mix-CFU, 59 ± 4.0%; and total, 50.0 ± 7.0%). These findings show that SeV could prove to be a promising vector for efficient gene transfer to CB HSCs, while preserving their ability to reconstitute the entire hematopoietic series.

Original languageEnglish
Pages (from-to)272-277
Number of pages6
JournalGene Therapy
Volume10
Issue number3
DOIs
Publication statusPublished - Feb 1 2003

Fingerprint

Sendai virus
Hematopoietic Stem Cells
Fetal Blood
Genes
Stem Cells
Green Fluorescent Proteins
Blood Cells
Fish Proteins
Granulocyte-Macrophage Progenitor Cells
Erythroid Precursor Cells
Cell Lineage
Retroviridae
Genetic Therapy
Cell Differentiation
Cell Cycle
Cytokines

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells. / Jin, C. H.; Kusuhara, K.; Yonemitsu, Y.; Nomura, A.; Okano, S.; Takeshita, H.; Hasegawa, M.; Sueishi, K.; Hara, T.

In: Gene Therapy, Vol. 10, No. 3, 01.02.2003, p. 272-277.

Research output: Contribution to journalReview article

Jin, CH, Kusuhara, K, Yonemitsu, Y, Nomura, A, Okano, S, Takeshita, H, Hasegawa, M, Sueishi, K & Hara, T 2003, 'Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells', Gene Therapy, vol. 10, no. 3, pp. 272-277. https://doi.org/10.1038/sj.gt.3301877
Jin, C. H. ; Kusuhara, K. ; Yonemitsu, Y. ; Nomura, A. ; Okano, S. ; Takeshita, H. ; Hasegawa, M. ; Sueishi, K. ; Hara, T. / Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells. In: Gene Therapy. 2003 ; Vol. 10, No. 3. pp. 272-277.
@article{4bdcfce24e6946a2a44e6ebb38096e81,
title = "Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells",
abstract = "Hematopoietic stem cells (HSCs) are a promising target for gene therapy, however, the low efficiencies of gene transfer using currently available vectors face practical limitations. We have recently developed a novel and efficient gene transfer agent, namely recombinant Sendai virus (SeV), and we have here characterized SeV-mediated gene transfer to human cord blood (CB) HSCs and primitive progenitor cells (PPC) using the jelly fish green fluorescent protein (GFP) gene. Even at a relatively low titer (10 multiplicity of infections), SeV achieved highly efficient GFP expression in CB CD34+ cells (85.5 ± 5.8{\%}), as well as more immature CB progenitor cells, CD34+AC133+ (88.2 ± 3.7{\%}) and CD34+CD38- (84.6 ± 5.7{\%}) cells, without cytokines prestimulation, that was a clear contrast to the features of gene transfer using retroviruses. SeV-mediated gene transfer was not seriously affected by the cell cycle status. In vitro cell differentiation studies revealed that gene transfer occurred in progenitor cells of all lineages (GM-CFU, 73.0 ± 11.1{\%}; BFU-E, 24.7 ± 4.0{\%}; Mix-CFU, 59 ± 4.0{\%}; and total, 50.0 ± 7.0{\%}). These findings show that SeV could prove to be a promising vector for efficient gene transfer to CB HSCs, while preserving their ability to reconstitute the entire hematopoietic series.",
author = "Jin, {C. H.} and K. Kusuhara and Y. Yonemitsu and A. Nomura and S. Okano and H. Takeshita and M. Hasegawa and K. Sueishi and T. Hara",
year = "2003",
month = "2",
day = "1",
doi = "10.1038/sj.gt.3301877",
language = "English",
volume = "10",
pages = "272--277",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells

AU - Jin, C. H.

AU - Kusuhara, K.

AU - Yonemitsu, Y.

AU - Nomura, A.

AU - Okano, S.

AU - Takeshita, H.

AU - Hasegawa, M.

AU - Sueishi, K.

AU - Hara, T.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Hematopoietic stem cells (HSCs) are a promising target for gene therapy, however, the low efficiencies of gene transfer using currently available vectors face practical limitations. We have recently developed a novel and efficient gene transfer agent, namely recombinant Sendai virus (SeV), and we have here characterized SeV-mediated gene transfer to human cord blood (CB) HSCs and primitive progenitor cells (PPC) using the jelly fish green fluorescent protein (GFP) gene. Even at a relatively low titer (10 multiplicity of infections), SeV achieved highly efficient GFP expression in CB CD34+ cells (85.5 ± 5.8%), as well as more immature CB progenitor cells, CD34+AC133+ (88.2 ± 3.7%) and CD34+CD38- (84.6 ± 5.7%) cells, without cytokines prestimulation, that was a clear contrast to the features of gene transfer using retroviruses. SeV-mediated gene transfer was not seriously affected by the cell cycle status. In vitro cell differentiation studies revealed that gene transfer occurred in progenitor cells of all lineages (GM-CFU, 73.0 ± 11.1%; BFU-E, 24.7 ± 4.0%; Mix-CFU, 59 ± 4.0%; and total, 50.0 ± 7.0%). These findings show that SeV could prove to be a promising vector for efficient gene transfer to CB HSCs, while preserving their ability to reconstitute the entire hematopoietic series.

AB - Hematopoietic stem cells (HSCs) are a promising target for gene therapy, however, the low efficiencies of gene transfer using currently available vectors face practical limitations. We have recently developed a novel and efficient gene transfer agent, namely recombinant Sendai virus (SeV), and we have here characterized SeV-mediated gene transfer to human cord blood (CB) HSCs and primitive progenitor cells (PPC) using the jelly fish green fluorescent protein (GFP) gene. Even at a relatively low titer (10 multiplicity of infections), SeV achieved highly efficient GFP expression in CB CD34+ cells (85.5 ± 5.8%), as well as more immature CB progenitor cells, CD34+AC133+ (88.2 ± 3.7%) and CD34+CD38- (84.6 ± 5.7%) cells, without cytokines prestimulation, that was a clear contrast to the features of gene transfer using retroviruses. SeV-mediated gene transfer was not seriously affected by the cell cycle status. In vitro cell differentiation studies revealed that gene transfer occurred in progenitor cells of all lineages (GM-CFU, 73.0 ± 11.1%; BFU-E, 24.7 ± 4.0%; Mix-CFU, 59 ± 4.0%; and total, 50.0 ± 7.0%). These findings show that SeV could prove to be a promising vector for efficient gene transfer to CB HSCs, while preserving their ability to reconstitute the entire hematopoietic series.

UR - http://www.scopus.com/inward/record.url?scp=0037320759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037320759&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3301877

DO - 10.1038/sj.gt.3301877

M3 - Review article

C2 - 12571635

AN - SCOPUS:0037320759

VL - 10

SP - 272

EP - 277

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 3

ER -